CD274 and lung cancer: An adverse prognostic value of PD‐L1 has already been demonstrated in other cancers, such as non‐small cell lung cancer, pancreatic undifferentiated carcinoma, thyroid, and prostate cancer (Lenouvel et al., 2020, 2021; Luchini et al., 2018; Shen et al., 2021).